secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001104659-24-027791
Event type: litigation
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics moves to block Liquidia's PH-ILD product with preliminary injunction and FDA suit
--------------------------------------------------------------------------------

- Filed preliminary injunction motion in Delaware on Feb 26, 2024, alleging Liquidia's PH-ILD product infringes U.S. Patent No. 11,826,327 (expires 2042).
- Separately sued FDA in D.C., arguing Liquidia must submit a new NDA for PH-ILD, which would trigger a 30-month stay.
- Liquidia's inhaled treprostinil is tentatively approved for PAH but not PH-ILD; United's Tyvaso is approved for both PAH and PH-ILD.
- If injunction or stay granted, Liquidia cannot market its product for PH-ILD while patent litigation proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000110465924027791/0001104659-24-027791-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000110465924027791/tm247282d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-027791

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer